Development of new kinase inhibitors as targeted cancer therapeutics = 표적항암제로서 새로운 키나아제 저해제의 개발에 관한 연구

Cited 0 time in webofscience Cited 0 time in scopus
  • Hit : 420
  • Download : 0
This thesis is about development of new kinase inhibitors as targeted cancer therapeutics. The research has two main purposes; one is producing new anticancer agent able to overcome resistance, a major problem faced in present clinical treatment and the other is investigating cancer involved bio-mechanism which has not been established clearly from a biological point. Part 1. Discovery of New Benzothiazole-based Derivatives as Potent Breakpoint Cluster Region-Abelson Kinase and T315I Mutant Inhibitors The existence of drug resistance caused by mutations in the break-point cluster region-Abelson tyrosine kinase (BCR-ABL) kinase domain remains a clinical challenge due to limited effective treatment options for chronic myeloid leukemia (CML). Herein we report a novel series of benzothiazole-based inhibitors that are effective against wild-type and T315I mutant BCR-ABL kinases. The original hit compound, nocodazole, was extensively modified through a structure-based drug design strategy, especially by varying the groups at the C2 and C6 positions of the scaffold. In addition, the introduction of water-solubilizing groups at the terminal ethyl group resulted in enhanced physicochemical properties and potency in cellular inhibition. Several compounds inhibited the kinase activity of both wild-type BCR-ABL and the T315I mutant with IC50 values in the picomolar range and exhibited good antiproliferative effects on Ba/F3 cell lines transformed with either wild-type or T315I mutant BCR-ABL. Keywords: break-point cluster region-Abelson tyrosine kinase, chronic myeloid leukemia, benzothaizole, T315I mutation Part 2. Study of Cross Talk between Trk and PI3K with Development of 7-Azaindole-based Inhibitors Having Anticancer and Antiangiogenic Activity As Phosphatidylinositol-3-kinase (PI3K) is a downstream effector of Tropomyosin-related kinase (Trk), two kinases are closely related in cell signal transduction. Each kinase is an important therapeutic target in cancer...
Advisors
Hong, Sung-Wooresearcher홍승우
Description
한국과학기술원 : 화학과,
Publisher
한국과학기술원
Issue Date
2014
Identifier
568649/325007  / 020088067
Language
eng
Description

학위논문(박사) - 한국과학기술원 : 화학과, 2014.2, [ v, 84 p. ]

Keywords

Targeted Cancer Therapeutics; 구조기반 약물설계; 혈관신생반응; 만성골수성 백혈병; 키나아제; 표적 항암제; kinase; BCR-ABL; PI3K; Trk; chronic myelogenous leukaemia; angiogenesis; structure based drug design

URI
http://hdl.handle.net/10203/196458
Link
http://library.kaist.ac.kr/search/detail/view.do?bibCtrlNo=568649&flag=dissertation
Appears in Collection
CH-Theses_Ph.D.(박사논문)
Files in This Item
There are no files associated with this item.

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0